Novo Nordisk, which is owned by Novo Holdings, will directly purchase the Bloomington location and two other fill-finish sites in Europe from its parent company. Catalent, a third-party manufacturer ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations on Wednesday. Here’s what you need to know ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

Novo Holdings is the controlling shareholder for Novo Nordisk, the Danish pharmaceutical giant that manufactures Ozempic and Wegovy. Amid the race to boost production of weight loss drugs, Novo ...

Novo Nordisk is not the only company that has realized the potential of the GLP-1 market, ... Agnani (Italy), Brussels (Belgium) and Bloomington (United States). Through this acquisition, ...

Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity ... Brussels in Belgium, and Bloomington, ...

Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ... Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills.

Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug that made it onto the market outside the company's approved supply chain.